Lansoprazole : An update of its place in the management of acid-related disorders

• Published in: Drugs (New York, N.Y.) Vol. 61; no. 12; pp. 1801 - 1833
• Main Authors: MATHESON, Anna J, JARVIS, Blair
• Format: Journal Article
• Language: English
• Published: Auckland Adis International 2001
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - adverse effects; Anti-Ulcer Agents - pharmacology; Anti-Ulcer Agents - therapeutic use; Biological and medical sciences; Digestive system; Dyspepsia - drug therapy; Gastrointestinal Diseases - drug therapy; Gastrointestinal Diseases - etiology; Humans; Lansoprazole; Medical sciences; Omeprazole - administration & dosage; Omeprazole - adverse effects; Omeprazole - analogs & derivatives; Omeprazole - pharmacology; Omeprazole - therapeutic use; Peptic Ulcer - chemically induced; Peptic Ulcer - drug therapy; Pharmacology. Drug treatments; Dyspepsia; Toxicity; Esophageal disease; Spirillaceae; H; Review; K; Eradication; Proton pump inhibitor; Helicobacter pylori; Antisecretory agent; Bacteria; Ulcer; Gastric disease; Human; Gastroesophageal reflux; Stomach; Spirillales; Enzyme; Treatment efficiency; Enzyme inhibitor; Hypersecretion; Infection; Non steroidal antiinflammatory agent; Chemotherapy; Treatment; Acids; Benzimidazole derivatives; Bacteriosis; Digestive diseases; Hydrolases; exchanging ATPase; Pharmacokinetics; Anastomotic ulcer; Lansoprazole
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/00003495-200161120-00011

Lansoprazole is an inhibitor of gastric acid secretion and also exhibits antibacterial activity against Helicobacter pylori in vitro. Current therapy for peptic ulcer disease focuses on the eradication of H. pylori infection with maintenance therapy indicated in those patients who are not cured of H. pylori and those with ulcers resistant to healing. Lansoprazole 30 mg combined with amoxicillin 1g, clarithromycin 250 or 500mg, or metronidazole 400 mg twice daily was associated with eradication rates ranging from 71 to 94%, and ulcer healing rates were generally >80% in well designed studies. In addition, it was as effective as omeprazole- or rabeprazole-based regimens which included these antimicrobial agents. Maintenance therapy with lansoprazole 30 mg/day was significantly more effective than either placebo or ranitidine in preventing ulcer relapse. Importantly, preliminary data suggest that lansoprazole-based eradication therapy is effective in children and the elderly. In the short-term treatment of patients with gastro-oesophageal reflux disease (GORD), lansoprazole 15, 30 or 60 mg/day was significantly more effective than placebo, ranitidine 300 mg/day or cisapride 40 mg/day and similar in efficacy to pantoprazole 40 mg/day in terms of healing of oesophagitis. Lansoprazole 30 mg/day, omeprazole 20 mg/day and pantoprazole 40 mg/day all provided similar symptom relief in these patients. In patients with healed oesophagitis. 12-month maintenance therapy with lansoprazole 15 or 30 mg/day prevented recurrence and was similar to or more effective than omeprazole 10 or 20 mg/day. Available data in patients with NSAID-related disorders or acid-related dyspepsia suggest that lansoprazole is effective in these patients in terms of the prevention of NSAID-related gastrointestinal complications, ulcer healing and symptom relief. Meta-analytic data and postmarketing surveillance in >30,000 patients indicate that lansoprazole is well tolerated both as monotherapy and in combination with antimicrobial agents. After lansoprazole monotherapy commonly reported adverse events included dose-dependent diarrhoea, nausea/vomiting, headache and abdominal pain. After short-term treatment in patients with peptic ulcer, GORD, dyspepsia and gastritis the incidence of adverse events associated with lansoprazole was generally < or = 5%. Similar adverse events were seen in long-term trials, although the incidence was generally higher (< or = 10%). When lansoprazole was administered in combination with amoxicillin, clarithromycin or metronidazole adverse events included diarrhoea, headache and taste disturbance. In conclusion, lansoprazole-based triple therapy is an effective treatment option for the eradication of H. pylori infection in patients with peptic ulcer disease. Preliminary data suggest it may have an important role in the management of this infection in children and the elderly. In the short-term management of GORD, lansoprazole monotherapy offers a more effective alternative to histamine H2-receptor antagonists and initial data indicate that it is an effective short-term treatment option in children and adolescents. In adults lansoprazole maintenance therapy is also an established treatment option for the long-term management of this chronic disease. Lansoprazole has a role in the treatment and prevention of NSAID-related ulcers and the treatment of acid-related dyspepsia; however, further studies are needed to confirm its place in these indications. Lansoprazole has emerged as a useful and well tolerated treatment option in the management of acid-related disorders.